By Fineline Cube 
French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for $9.1 billion, with the total reaching $9.5 billion if potential milestone payments are included. This strategic move will bolster Sanofi’s portfolio in rare immunological diseases.
Blueprint’s Product Pipeline
The acquisition grants Sanofi access to Blueprint’s product pipeline, including Ayvakit/Ayvakyt (avapritinib), the world’s first and only therapy for systemic mastocytosis (SM), next-generation KIT D816V inhibitor elenestinib, and BLU-808, an oral wild-type KIT inhibitor. Ayvakit/Ayvakyt generated $479 million in sales in 2024 and $150 million in the first quarter of 2025.
Financial and Strategic Impact
The transaction, expected to close in Q3 2025, will be financed through cash and new debt. Sanofi anticipates rapid margin accretion and incremental operating income and EPS growth post-2026, highlighting the acquisition’s potential to strengthen its position in immunology and oncology.-Fineline Info & Tech